Theratechnologies (THTX) announced that the United States FDA has assigned a Prescription Drug User Fee Act goal date of March 25, 2025 to the company’s recently submitted supplemental Biologics License Application for the F8 formulation of tesamorelin. If approved by the FDA, the F8 formulation is intended to replace the F4 formulation, which is sold in the U.S. under the trade name EGRIFTA SV. The new formulation is patent protected in the U.S. until 2033.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on THTX:
- Theratechnologies announces preliminary tolerability, efficiacy data for TH1902
- Theratechnologies Shows Promise in Ovarian Cancer Trial
- Theratechnologies Secures Financing for Strategic Growth
- Theratechnologies Expands Portfolio with Ionis Deal
- Theratechnologies enters exclusive licensing agreement with Ionis
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
